Abstract
Plasmodial bifunctional dihydrofolate reductase-thymidylate synthase (DHFR-TS) is a validated antimalarial drug target. In this study, expression of the putative dhfr-ts of Plasmodium ovale rescued the DHFR chemical knockout and a TS null bacterial strain, demonstrating its DHFR and TS catalytic functions. PoDHFR-TS was expressed in Escherichia coli BL21 (DE3) and affinity purified by Methotrexate Sepharose column. Biochemical and enzyme kinetics characterizations indicated that PoDHFR-TS is similar to other plasmodial enzymes, albeit with lower catalytic activity but better tolerance of acidic pH. Importantly, the PoDHFR from Thai isolate EU266602 remains sensitive to the antimalarials pyrimethamine and cycloguanil, in contrast to P. falciparum and P. vivax isolates where resistance to these drugs is widespread.
Abbreviations: DHFR, dihydrofolate reductase; TS, thymidylate synthase; JR, junction region; Pf, Plasmodium falciparum; Po, P. ovale; Pv, P. vivax; Tc, Trypanosoma cruzi; CYC, cycloguanil; DTT, dithiothreitol; dUMP, deoxyuridine monophosphate; EDTA, ethylenediaminetetraacetic acid; HCOH, formaldehyde; H2folate, 7,8-dihydrofolate; IPTG, iso-propyl-beta-d-thio-galactopyranoside; LC-MS/MS, liquid chromatography-mass spectrometry; MTX, methotrexate; NADPH, nicotinamide adenine dinucleotide phosphate; PVDF, polyvinylidene fluoride; PYR, pyrimethamine; TES, N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid; TMP, trimethoprim; 6-[3H] FdUMP, 5-fluoro 2′-deoxyuridine 5′-monophosphate; (6R)-CH2H4folate, 5,10-methylene tetrahydrofolate; MM, minimum media
Keywords: Plasmodium ovale, Dihydrofolate reductase-thymidylate synthase, Antifolates
Graphical abstract
Highlights
► Polymorphism of P. ovale dihydrofolate reductase-thymidylate synthase was identified. ► Bacterial complementation assay revealed the function of the putative PoDHFR-TS. ► The protein was expressed and purified. ► Biochemical and kinetic properties including antifolate sensitivity were determined.
1. Introduction
Malaria is caused by Plasmodium protozoan transmitted by female Anopheles mosquitoes. There are five species that infect human, namely, P. falciparum (Pf), P. vivax (Pv), P. malariae (Pm), P. ovale (Po), and P. knowlesi (Pk). P. falciparum and P. vivax are the most prevalent species found in most endemic areas, whereas P. malariae and P. ovale infections have patchy and limited distribution [1–3]. P. knowlesi is a zoonosis parasite recently reported to be the fifth human-infecting malaria species [4]. Mixed infections by these parasite species also are generally observed [5].
Parasite detection by blood smears observed under a light microscope is the most common tool used in the field in order to assess the levels of clinical infection and for epidemiological surveillances. However, differentiation of Plasmodium species, especially of P. ovale, P. malariae, and P. knowlesi by light microscopy can be challenging [6]. Indeed, the detection limit of light microscopy has been suggested to be a cause of low incidences reported for malaria cases caused by these species [7]. In addition, information on drug resistance is important in designing strategic plans to control the spread of malaria infection and providing effective treatment for the patients. These data are well established for P. falciparum and P. vivax, but they have been overlooked for the others. It is well established that a drug deployment policy for one particular malaria parasite species can lead to selection pressure on other Plasmodium species, as exemplified by the spillover of antifolate resistant phenotype observed in P. falciparum into P. vivax [8–10].
Unlike P. falciparum, where continuous in vitro culture has been routinely established [11], cultures of the other malaria parasite species, including P. ovale, have yet to be established. Therefore, determination of in vitro drug susceptibility in these parasites cannot be made. However, the putative gene of P. ovale dihydrofolate reductase-thymidylate synthase (PoDHFR-TS), a known antifolate target, has recently been identified and sequenced [12]. Here, we report the cloning and heterologous expression of PoDHFR-TS gene from a Thai isolate (EU266602), together with protein purification. Bacterial complementation and biochemical characterization were performed to verify the coding sequence as DHFR-TS. The sensitivity to antifolate antimalaria of the expressed PoDHFR-TS was assessed.
2. Materials and methods
2.1. Molecular cloning of P. ovale dihydrofolate reductase-thymidylate synthase (podhfr-ts) gene
The genomic DNA was prepared from a Thai isolate (EU266602), for which the P. ovale infection was confirmed using 2 PCR protocols based on the amplification of species specific small subunit rRNA (SSU rRNA) and linker region (or junction region; jr) of the dhfr-ts genes [13,14]. Full-length podhfr-ts (1920 bp) was generated by an overlap extension PCR technique [15]. The dhfr-jr and jr-ts DNA fragments were separately amplified and each fragment contained a 54 bp overlapping flanking sequence in order to mediate homologous recombination that generated the full-length podhfr-ts as described below. Unless otherwise indicated, PCR reactions were carried out in a total volume of 50 μL containing 100 ng of DNA template, 125 μM dNTPs, 250 nM each of sense and antisense primers, and 3 U of Pfu polymerase (Promega Corporation, WI, USA).
The sequence coding for podhfr-jr was amplified from pGemT-podhfr plasmid using primers 5′PoDHFR (ATGGAGGAAGTCTCAGAGGTTTTC) and 3′Po-link (GATGATCCTTTTCCGTGATGAGAAG). PCR thermocycling conditions were as follows: 95 °C for 5 min; 30 cycles of 94 °C for 1 min, 50 °C for 1 min and 72 °C for 2 min; and a final heating at 72 °C for 5 min. The amplicon (863 bp) was purified using GeneJET™ Plasmid Miniprep Kit (Fermentas, Burlington, Canada).
The pojr-ts fragment was amplified directly from P. ovale genomic DNA using primers 5′Po-link (GCAGGAGCTACCTCTTCCATG) and 3′PoTS (TTAGGCGGCCATATCCATAGTGAT). Taq DNA polymerase was used in the PCR with the following thermocycling conditions: 1 cycle of 95 °C for 5 min; 30 cycles of 94 °C 1 min, 55 °C 1 min and 72 °C 1 min; and a final cycle of 72 °C 5 min. The expected jr-ts amplicon (1134 bp) was purified from 0.8% agarose using GeneJET™ Gel Extraction Kit (Fermentas, Burlington, Canada). The extracted pojr-ts was ligated into T-overhang pTZ57R/T plasmid (Fermentas, Burlington, Canada) and the resulting pTZ57R/T-pojr-ts plasmid construct was used as a template to re-amplify pojr-ts sequence using conditions as described above, except that Pfu polymerase and an elongation time of 2.5 min were used.
In order to obtain the full-length podhfr-ts, 50 ng each of the podhfr-jr and pojr-ts fragments were combined and PCR was performed without addition of primers using the following thermocycling conditions: 1 cycle of 95 °C for 5 min; 30 cycles of 94 °C for 1 min, 70 °C for 1 min and 72 °C for 2.5 min; and a final step at 72 °C for 5 min. Then 1.0 μL of the PCR solution together with primers 5′NhePo (CACCGCTAGCATGGAGGAAGTCTCAGAGGT; Nhe I restriction site as underlined) and 3′PoTS were used in the subsequent PCR with the following thermocycling conditions: 1 cycle of 95 °C for 5 min; 30 cycles of 94 °C for 1 min, 60 °C for 1 min, and 72 °C for 4 min; and a final step at 72 °C for 5 min.
The podhfr-ts was digested with Nhe I and ligated into pET17b (Invitrogen) vector, which had previously been digested with Nhe I and EcoR V. The insert sequence was analyzed by 1st BASE (Selangor Darul Ehsan, Malaysia) and Genome Institute (Pathumthani, Thailand).
Site-directed mutagenesis experiments were performed to correct any mutations occurring. The reaction contained 50 ng template, 125 μM dNTPs, 250 nM sense and antisense primers, and 3 U of Pfu polymerase. Similar PCR conditions as described above were employed, except that the condition for annealing and elongation was 61 °C for 1 min and 72 °C for 11 min respectively. Sense and antisense primers used to correct the mutations are listed in Table 1, which shows the corrected nucleotides (underlined).
Table 1.
Corrected mutation | Sense (F) and antisense (R) primers used |
---|---|
I225T | F; GTAGTAACGGAACCACATTAGACTTTCTAATTTA |
R; TAAATTAGAAAGTCTAATGTGGTTCCGTTACTAC | |
236K | F; TTACAGTAGGAAAAAAAAAGACACACAAAATG |
R; CATTTTGTGTGTCTTTTTTTTTCCTACTGTAA | |
S258T | F; GCTACAGCTACAGCGACATGGCCAGGAATAG |
R; CTATTCCTGGCCATGTCGCTGTAGCTGTAGC | |
R303W | F; GGAGCAGAATGGTGGGGAAATATGGCT |
R; AGCCATATTTCCCCACCATTCTGCTCC | |
H476Y, D478N | F; GCTGAATATACAAATATGTATGATAATTATGAAAATAAAGGAATTG |
R; CAATTCCTTTATTTTCATAATTATCATACATATTTGTATATTCAGC |
Corrected nucleotides are underlined.
2.2. Complementation assay
For DHFR activity test, E. coli BL21 (DE3) was transformed with pET17bPoDHFR-TS and plated on LB agar containing 100 μg/ml ampicillin. A single colony of transformed cell was cultured in 5 mL of LB broth supplemented with 100 μg/ml ampicillin at 37 °C until OD600 reached 0.8. Cells (5 μL) were spotted on minimum media (MM) agar plate supplemented with 100 μg/ml ampicillin in either the presence or absence of 4 μM trimethoprim (TMP), and incubated at 37 °C overnight. Cells transformed with pET17b were used as a negative control.
For TS activity test, a Thy¯ E. coli strain χ 2913recA-DE3 (Δ thyA572, recA56) [16] was used. Similar experiment to that described for DHFR activity test was performed, except that MM agar plate contained 100 μg/ml ampicillin in the presence or absence of 50 μg/ml thymidine.
2.3. PoDHFR-TS enzyme expression and purification
E. coli BL21 (DE3) harboring pET17bPoDHFR-TS plasmid was used for expression of PoDHFR-TS. Cells were grown in SOB medium supplemented with 100 μg/ml ampicillin at 37 °C until OD600 reached 1.0, when expression of PoDHFR-TS was induced by supplementation with 0.4 mM IPTG. Cells were grown at 16 °C for 20 h, collected by centrifugation at 10,000 g for 10 min and lysed using a French press (Thermo Dynamics Ltd., Nova Scotia, Canada) at 69 MPa in buffer A (20 mM potassium phosphate pH 7.0, 50 mM KCl, 0.1 mM EDTA, 10 mM DTT, and 20% (v/v) glycerol). Cell lysate was centrifuged at 27,000 g for 1 h, and PoDHFR-TS in the supernatant was purified using MTX-affinity chromatography as previously described [17]. Briefly, the supernatant was loaded onto MTX-Sepharose pre-equilibrated with buffer A and the nonspecific binding proteins were washed by buffer A containing 1 M KCl. PoDHFR-TS was eluted by buffer B (50 mM TES pH 8.0, 0.1 mM EDTA, 10 mM DTT, 50 mM KCl, 20% (v/v) glycerol, and 4 mM H2folate).
Fractions containing DHFR activity was further purified by passage over a Sephacryl S-200 HR column (2.5 × 90 cm), using buffer A at a flow rate of 0.2 mL/min. Another approach used for PoDHFR-TS purification was Q-Sepharose anion-exchange chromatography (3 × 5 cm column) using a linear salt gradient from 0.05 to 1 M NaCl in buffer A (100 mL total volume). SDS-PAGE was used to demonstrate protein expression and purity.
2.4. PoDHFR-TS enzyme identification
Protein bands observed on Coomassie blue-stained SDS-PAGE were subjected to an in-gel tryptic digestion, and identified by LC-MS/MS (Genome Institute, Pathumthani, Thailand). All MS/MS spectra were searched against database using SEQUEST algorithm by filtering of cross-correlation score (Xcorr) versus charge state (+ 1 ≥ 1.5,+2 ≥ 2.0,+3 ≥ 2.5) with protein probability of a minimum of 1.00 × 10− 3) and Sp (Primary Score) of greater than 500.
For N-terminal sequence analysis, protein bands on SDS-PAGE were transferred onto PVDF membrane (Millipore, Massachusetts, USA) and subsequently sequenced by Edman degradation method (AltaBioscience, Birmingham, UK).
2.5. Kinetic characterization of DHFR and TS activities
DHFR enzyme activity was measured spectrophotometrically at 340 nm for the decrease of NADPH substrate and the activity was calculated using a molar absorptivity (ε340) of 12,300 M− 1 cm− 1 [18]. One unit of DHFR activity is defined as the amount of the enzyme that catalyzes the reduction of 1 μmol of substrate per minute at 25 °C. The assay solution (1 mL) contained 50 mM TES pH 7.0, 75 mM β-mercaptoethanol, 1 mM EDTA, 100 μM H2folate, 100 μM NADPH, 1 mg/ml BSA and enzyme. Km values for H2folate and NADPH were conducted at a range of 1–100 μM for one substrate while keeping fixed the concentration of the other at 100 μM. All reactions were initiated with 0.005 enzyme unit and performed in a Hewlett Packard UV–VIS spectrophotometer (HP8453). Data were fitted to a Michaelis–Menten equation using a non-linear least-square fitting module of KaleidaGraph™ software (Synergy Software, Pennsylvania, USA).
TS enzyme activity was measured spectrophotometrically by monitoring at 25 °C the increase in absorbance at 340 nm due to the formation of H2folate, performed with an approximately 0.006 enzyme unit in TS buffer (50 mM TES pH 7.4, 25 mM MgCl2, 6.5 mM HCOH, 1 mM EDTA and 75 mM β-mercaptoethanol), 150 μM of (6R)-CH2H4folate (Merck Eprova AG, Switzerland), and 125 μM dUMP (to initiate reaction). Enzyme activity was calculated using a molar extinction coefficient (ε340) of 6,400 M− 1 cm− 1 [19]. One unit of TS activity is defined as the amount of the enzyme that catalyzes the formation of 1 μmol of product per minute. Km values for (6R)-CH2H4folate and dUMP were performed using a saturation concentration of one substrate (150 μM for (6R)-CH2H4folate and 125 μM for dUMP) and varying the concentration of the other (2–150 μM for (6R)-CH2H4folate and 1–125 μM for dUMP), and data were analyzed as described for DHFR.
2.6. 6-[3H] FdUMP thymidylate synthase labeling activity
TS labeling by 6-[3H] FdUMP was performed as previously described [20–22]. In brief, 2 μg of purified PoDHFR-TS were incubated with 5 μL of 3 mM (6R)-CH2H4folate, 0.25 μL of 66 μM 6-[3H] FdUMP (15 Ci/mmol, Moravek Biochemicals, California, USA) in TS buffer (20 μL final volume) at 25 °C for 1 h. The reaction was stopped by adding SDS dye solution and boiling for 10 min. The protein complex was analyzed by 12.5% SDS-PAGE. The Coomassie-blue dye stained gel was soaked in autoradiography enhancer (NEN™, Dupont) for 1 h at 25 °C with gently shaking, dried at 80 °C, and exposed to Hyperfilm (Amersham Hyperfilm ECL™, GE Healthcare Life Science) at − 80 °C for one day. The procedure was performed with Trypanosoma cruzi DHFR-TS as positive control and with PvDHFR as a negative control.
2.7. Effect of pH on reaction catalysis
The pH dependences for DHFR and TS activities were monitored as described in Section 2.5 but using polybuffer in the pH range of 4–9.5 at 25 °C. For assay of DHFR activity the polybuffer was composed of 50 mM acetic acid, 50 mM MES, 100 mM Tris-Cl, and 10 mM β-mercaptoethanol, and for TS activity the polybuffer buffer was supplemented with 25 mM MgCl2, 6.5 mM HCOH, and 1 mM EDTA. Catalytic constant was plotted as a function of pH.
2.8. Inhibition of DHFR by antifolates
Inhibition of DHFR activity by antifolate compounds [pyrimethamine (PYR) and cycloguanil (CYC)] were determined in 1 mL of DHFR assay solution containing 100 μM NADPH and H2folate, together with 5 nM–1 μM inhibitors. Reaction was initiated by adding 0.01 enzyme unit. Inhibition constant (Ki) was calculated from a non-linear least-square fit of data using KaleidaGraph™ software. The type of inhibition by antifolate compounds was analyzed using DHFR assay solution containing 100 μM NADPH with varying (2.5 μM–12.5 μM) H2folate concentrations. Data were analyzed using a Lineweaver–Burk plot of the reciprocal values of initial velocity and concentrations of H2folate.
3. Results and discussion
3.1. Analysis of PoDHFR-TS sequence
A recent study by multi-locus sequence analysis identified 2 nonrecombining sympatric forms of P. ovale, classic and variant types, or P. ovale curtisi and P. ovale wallikeri respectively [12]. At present, 18 podhfr-ts sequences derived from field isolates of different geographic regions have been reported [12]. Sequence comparisons reveal dimorphic patterns in PoDHFR-TS (Table 2), and the variant type contains 2 amino acids more than that of the classic type (639 versus 637 residues) in the junction region (Fig. 1A). P. ovale variant type is mostly observed for Thai isolates (8 out of 12), while the classic type is from Sao Tome (2 out of 6) and Guinea-Bissau (4 out of 6) (Table 2). It is noted that none of the parasites from Thai isolates belong to the classic type. Examples of dimorphic patterns observed in DHFR domain are demonstrated — F/Y31, S/N33, C/Y49, I/V187, D/E204, E/K207, and A/T209 (Table 2). These polymorphisms are not equivalent to those associated with antifolate resistance in PfDHFR-TS and PvDHFR-TS. Thus, it is unlikely that the PoDHFR-TS enzyme would be resistant to antifolates, unless these polymorphisms significantly affect the binding characteristics of the active site. Point mutations in Plasmodium DHFR responsible for antifolate resistance have been well characterized for P. falciparum (A16V, N51I, C59R, S108N, and I164L) and P. vivax (F57L, S58R, T61M, S117N, and I173L) [23,24]. These residues in variant and classic PoDHFRs are identical — A15, N50, F57, S58, T61, S113, and I169 — which are similar to the wild-type sequence of other Plasmodium DHFRs (Table 2). The conserved R470 and C490 in PfDHFR-TS are important for TS activity [16], for which these residues are equivalent to R501 and C521 of PoDHFR-TS variant or R499 and C519 for the classic type (Fig. 1A). Using P. ovale strain EU266602, a variant type, as the reference sequence, a number of sequence variations were identified among different isolates such as E3Q/H, V4L, E6D, I39V, Y56C, I96M, Y164H , C166R, C178Y, I184M, and I212V. These variations were confirmed as the sequences of each isolate were derived from at least 2 colonies after cloning.
Table 2.
Accession no. | Origin | Amino acid number in DHFR domain | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J03028 (Pf) | FCR3, Lab strain | 4 | 5 | 6 | 7 | 14 | 16 | 32 | 34 | 40 | 50 | 51 | 57 | 58 | 59 | 62 | 71 | 91 | 108 | 113 | 159 | 161 | 164 | 173 | 179 | 182 | 199 | 202 | 204 | 207 | |
Q | V | C | D | I | A/V | F | N | L | C | N/I | Y | F | C/R | T | E | D | S/N,T | P | Y | C | C I/L | F | I | I | E | E | E | I | |||
EU478859 (Pv) | India | 3 | 4 | 5 | 6 | 13 | 15 | 31 | 33 | 39 | 49 | 50 | 56 | 57 | 58 | 61 | 70 | 100 | 117 | 122 | 168 | 170 | 173 | 182 | 188 | 191 | 208 | 211 | 213 | 216 | |
D | L | S | D | I/L | A | F | P | L | C | N | Y | F/L | S/R | T/M | E | G | S | P | Y | C | I | C | I | I | E | E | Q | V | |||
AY846633 (Pm) | Thailand | 3 | 4 | 5 | 6 | 13 | 15 | 31 | 33 | 39 | 49 | 50 | 56 | 57 | 58 | 61 | 70 | 97 | 114 | 119 | 165 | 167 | 170 | 179 | 185 | 188 | 205 | 208 | 210 | 213 | |
E | V | S | D | I | A | F | T | L | S | N | Y | F | S | T | K | S | S | P | Y | C | I | C | I | I | E | E | V | I | |||
XM002258192 (Pk) | Malaysia | 3 | 4 | 5 | 6 | 13 | 15 | 31 | 33 | 39 | 49 | 50 | 56 | 57 | 58 | 61 | 70 | 100 | 117 | 122 | 168 | 170 | 173 | 182 | 188 | 191 | 208 | 208 | 213 | 216 | |
D | L | S | E | I | A | F | P | L | C | N | Y | F | S | T | E | T | S | P | Y | C | I | C | I | I | Q | E | Q | M | |||
Type | 3 | 4 | 5 | 6 | 13 | 15 | 31 | 33 | 39 | 49 | 50 | 56 | 57 | 58 | 61 | 70 | 96 | 113 | 118 | 164 | 166 | 169 | 178 | 184 | 187 | 204 | 207 | 209 | 212 | ||
EU266602 | Thailand | Variant | E | V | S | E | I | A | F | S | I | C | N | Y | F | S | T | K | I | S | P | Y | C | I | C | I | I | D | E | A | I |
GQ250091 | PNG | Variant | Q | L | . | D | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
EU266604 | Benin | Variant | Q | L | . | D | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | M | . | . | . |
EU266605 | Sao Tome | Variant | Q | L | . | D | . | . | . | . | V | . | . | C | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
EU266612 | Thailand | Variant | ND | ND | ND | ND | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
EU266613 | Thailand | Variant | ND | ND | ND | ND | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | H | . | . | . | . | . | . | . | . | . |
EU266614 | Thailand | Variant | ND | ND | ND | ND | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
EU266615 | Thailand | Variant | ND | ND | ND | ND | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | ||
EU266616 | Thailand | Variant | ND | ND | ND | ND | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | Y | . | . | . | . | . | . |
EU266617 | Thailand | Variant | ND | ND | ND | ND | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | T | . |
EU266618 | Thailand | Variant | ND | ND | ND | ND | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
GQ250090 | Variant | . | L | C | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | |
EU266606 | Sao Tome | Classic | H | . | C | D | . | . | Y | N | . | Y | . | . | . | . | . | N | . | . | . | . | . | . | . | . | V | E | K | T | . |
EU266607 | Sao Tome | Classic | ND | ND | ND | ND | . | . | Y | N | . | Y | . | . | . | . | . | N | . | . | L | . | . | . | . | . | V | E | K | T | . |
EU266608 | Guinea-Bissau | Classic | ND | ND | ND | ND | . | . | Y | N | . | Y | . | . | . | . | . | N | . | . | . | . | . | . | . | . | V | E | K | T | . |
EU266609 | Guinea-Bissau | Classic | ND | ND | ND | ND | . | . | Y | N | Y | . | . | . | . | . | D | M | . | . | . | . | . | . | . | V | E | K | T | . | |
EU266610 | Guinea-Bissau | Classic | ND | ND | ND | ND | . | . | Y | N | . | Y | . | . | . | . | . | N | . | . | . | . | R | . | . | . | V | G | K | T | . |
EU266611 | Guinea-Bissau | Classic | ND | ND | ND | ND | . | . | Y | N | . | Y | . | . | . | . | . | N | . | . | . | . | . | . | . | . | V | E | K | T | V |
3.2. Construction of podhfr-ts expression vector
Initial attempts to PCR amplify the open reading frame (ORF) of podhfr-ts from genomic DNA resulted in the production of partial gene sequences. Eventually, the full-length podhfr-ts was successfully amplified using an overlap extension PCR-based method (Fig. S). In this approach, podhfr and pots with flanking homologous sequence were synthesized first (Fig. S; PCR 2), and the amplicons were then used as templates and primers for sequence extension in the following PCR (Fig. S; PCR 3). Another PCR was required in order to obtain sufficient amounts of DNA for further cloning step (Fig. S; PCR 4). A major amplicon of 1920 bp was finally obtained (Fig. S; PCR 4). Reasons for the unsuccessful amplification of the full-length gene by direct PCR amplification from genomic DNA include primers annealing at non specific sites, and presence of DNA secondary structures due to the high AT content (67%) thereby hindering polymerase processivity.
Upon ligation at Nhe I and EcoR V sites, 3 amino acids, namely, methionine, alanine, and serine, are introduced upstream of the initiation methionine of PoDHFR-TS. Five missense mutations (T225I, ACA → ATA; T258S, ACA → TCA; W303R, TGG → AGG; Y476H, TAT → CAT; and N478D, AAT → GAT) and one missing nucleotide (A708) of K236 were found from the first expression construct generated. Amino acids T225, T258, W303, Y476, and N478 are conserved in all 18 isolates, in which the sequences were reported [12]. The errors observed were likely to be due to the use of multiple steps of PCR and of Taq DNA polymerase, a non proofreading DNA polymerase [25]. The sequence was corrected by site-directed mutagenesis and the final expression construct, pET17bPoDHFR-TS, encodes 642 amino acids, which share 65–75, 19–32, and 90% identities for the DHFR, JR, and TS domains, respectively, with other human plasmodial species (Fig. 1A).
3.3. Complementation assay
Bacterial complementation assays were carried out to provide preliminary evidence for DHFR and TS functions of the heterologously expressed protein. DHFR activity was investigated through its ability to complement bacterial cell activity in the presence of TMP, a specific bacterial DHFR inhibitor. E. coli transfected with pET17bPoDHFR-TS could grow on MM plate containing 4 μM TMP, whereas cells carrying an empty plasmid was suppressed (Fig. 2A). A similar strategy was employed for TS activity determination, using Thy¯ E. coli strain χ 2913recA-DE3. Such cells carrying pET17bPoDHFR-TS were able to grow in the absence of thymidine supplementation, as was required by untransfected control cells (Fig. 2B).
Since at present it is not possible to maintain P. ovale in continuous culture, this bacterial complementation assay provides a useful means to evaluate novel compounds with potential inhibitory properties directed against P. ovale DHFR and TS, as well as evaluating mutant enzymes from field isolates and constructed in the laboratory. A similar approach was recently used for screening antifolates for PvDHFR [26].
3.4. Enzyme expression and purification
Heterologous expression of recombinant PoDHFR-TS in E. coli BL21 (DE3) induced with 0.4 mM IPTG at 16 °C for 20 h was relatively low (~ 1%) as assessed by SDS-PAGE analysis (Fig. 3). Attempts to increase yield by varying host cell types and IPTG concentrations were unsuccessful (data not shown). The expressed PoDHFR-TS protein was purified using MTX-affinity chromatography, yielding 12 mg of enzyme, with a specific activity of 1.7 μmol/min/mg, from 1 L culture. Upon the analysis by SDS-PAGE, in addition to the expected protein band of 74 kDa, proteins of 35 and 32 kDa also were observed, accounting for 50% of the total protein in the gel (Fig. 3). Further purification by gel filtration and anion-exchange chromatographies failed to remove these smaller proteins (data not shown). These results are similar to those previously reported for the purification of heterologous expressed PfDHFR-TS, in which it was concluded that the phenomenon is the consequence of either protein degradation or premature termination of protein translation as evidenced from protein N-terminal sequencing results [22]. Although the smaller fragments may be from any region of PoDHFR-TS, as these fragments were co-purified by MTX-affinity chromatography, they were assumed to contain the DHFR domain. Further experiments to express PoDHFR-TS containing C-terminus tagged with either single or double hexa-histidine sequence to facilitate purification of the full-length PoDHFR-TS from the truncated fragments were equally fruitless (data not shown). The specific activities of the DHFR domain measured in the crude extracts derived from the expression of these latter constructs were significantly lower than that from pET17bPoDHFR-TS (data not shown), suggesting interference of DHFR activity by the presence of C-terminal histidine tags.
To determine the identities of 74, 35, and 32 kDa proteins, these bands were separately subjected to tryptic digestion and the tryptic peptides were analyzed by LC-MS/MS. The MS/MS spectra of these fragments were searched against an in-house created Plasmodium database using BioworkTM 3.3 software (Thermo Scientific, USA). The tryptic peptides of these three samples corresponded to PoDHFR-TS with the best score among Plasmodium DHFR-TS. The amino acid sequences of tryptic fragments of all three samples corresponded well to the in silico digested peptides in DHFR, JR, and TS domains (Fig. 1B).
To confirm the presence of PoDHFR-TS, Edman N-terminal sequence analysis was conducted. After methionine deblocking, the first 6 amino acid sequence obtained from 74 kDa protein was ASMEEV, perfectly matching the N-terminus of the recombinant PoDHFR-TS, which has an extra AS N-terminal sequence derived from cloning into Nhe I site of pET17b. Thus, the 74 kDa protein is the bona-fide full-length PoDHFR-TS, based on mass, MS and N-terminal sequencing data.
However, N-terminal sequencing of the 32- and 35-kDa bands did not produce unequivocal sequencing results, but indicated the presence of two polypeptides with N-terminal sequences ASMEEV (amino acids 1–4) and MKNVED (amino acids 337–342) present in the 32 kDa band, and ASMEEV and MYFSFN (amino acids 323–328) in the 35 kDa band. These polypeptide fragments are presumably due to a chymotrypsin-like proteolytic activity [27].
TS activity in the expressed PoDHFR-TS was determined by taking the advantage of the ability of FdUMP, a TS suicide inhibitor, to form a covalent adduct with TS. Autoradiography revealed that [3H] FdUMP labeled 32, 35 and 74 kDa bands (Fig. 3), in line with the data from LC-MS/MS and N-terminal sequencing.
It can be concluded that the bifunctional PoDHFR-TS had been obtained and had co-purified with truncated fragments containing both DHFR and TS domains. These results also suggest the existence of tight interactions between these domains. Mutations in the proteolytic cleavage region may prevent the production of such fragments during protein expression, with the caveat that the mutant protein does not affect enzyme activity.
3.5. Effect of pH on DHFR and TS activities
The relationship between steady state catalytic constant and pH for DHFR and TS demonstrated that the PoDHFR domain of the bifunctional PoDHFR-TS was active in both the acid and neutral ranges but the activity decreased at higher pH (Fig. 4). The optimum pH could not be determined owing to the instability of H2folate at pH < 4. Although Plasmodium DHFRs are conserved in sequence, the pH profile obtained for PoDHFR is different from those of PfDHFR and PvDHFR, which exhibit maximum activity around pH 7 [24,28]. However, a number of vertebrate DHFRs have higher activity in acidic pH [29], similar to our observation for PoDHFR. On the other hand, TS activity was similar at pH 7–9.
3.6. DHFR and TS kinetic properties
Steady state kinetic parameters for PoDHFR-TS as well as the inhibition constants for antifolates (PYR and CYC) were determined and are summarized in Table 3. The apparent Km values for NADPH and H2folate are similar to those of other Plasmodium DHFRs. It is worth noting that the DHFR domain of P. ovale enzyme is the least catalytically active, as its kcat is 9 and 2.5 folds lower than that of the wild-type PfDHFR and PvDHFR respectively. The TS domain of PoDHFR-TS also has half of the activity of that of other Plasmodium species.
Table 3.
Plasmodium enzyme | DHFR activity |
TS activity |
DHFR inhibition |
|||||
---|---|---|---|---|---|---|---|---|
Km [H2folate] (μM) | Km [NADPH] (μM) | kcat (s− 1) | Km [CH2H4folate] (μM) | Km [dUMP] (μM) | kcat (s− 1) | Ki [PYR] (nM) | Ki [CYC] (nM) | |
PoDHFR-TS | 2.42±0.25 | 3.71±0.51 | 8.5±0.6 | 5.92±0.77 | 1.44±0.16 | 0.50±0.07 | 0.67±0.08 | 0.96±0.15 |
PfDHFR-TS | 1.0±0.1a | 4.2±0.2a | 80a | 2.12±0.26b | 1.66±0.14b | 1.13b | 0.2±0.02c | 0.3±0.00c |
PvDHFR-TS | 1.6±0.1 | 1.1±0.2 | 21.2 | 2.77±0.71d | 3.72±0.67d | 1.20d | 0.21±0.03e | 0.31±0.04 |
a–e; data from [28], [16], [30], [31], and [26], respectively.
Standard kinetics double reciprocal plots revealed that PYR and CYC inhibited H2folate binding to PoDHFR domain in a competitive fashion (Fig. 5). The antimalarial antifolates, PYR and CYC, inhibited PoDHFR at nanomolar concentrations (Table 3), similar to other wild-type Plasmodium enzymes. Thus, P. ovale would appear to be sensitive to antifolates, but constant monitoring of resistance in the field is clearly warranted.
In summary, this study reports the cloning, sequencing and heterologous expression of podhfr-ts. Biochemical characterization of the purified recombinant bifunctional PoDHFR-TS showed that it was similar in kinetic properties with other wild-type Plasmodium species, but with anomaly pH activity profile, and that the DHFR domain was sensitive to the antifolates, PYR and CYC. Due to the availability of podhfr-ts, this paves the way for further structure–function relationship studies and drug susceptibility test of site-directed mutant enzymes, towards the goal of rational drug design directed against P. ovale.
The following are the supplementary materials related to this article.
Acknowledgements
This work was supported by grants from Cluster and Program Management Office (CPMO; BT-B-02-MG-BC-5006) and Synchrotron Light Research Institute-Public Organization (Grant 2-2549/LS01) to UL, and partially supported by Thailand Research Fund (TRF/DBG5480015) to PK. ST received scholarships from TRF Royal Golden Jubilee Ph.D. Program (grant no. PHD/0078/2548) and the Center for Innovation in Chemistry: PERCH-CIC. We are greatly indebted to Dr. Rudolf Moser (Merck Eprova AG, Switzerland) and Dr. Jarunee Vanichthanankul (National Center for Genetic Engineering and Biotechnology, Thailand) for gifts of 5,10-methylene tetrahydrofolate and T. cruzi DHFR-TS respectively. We also thank Prof. Prapon Wilairat for editing the manuscript.
References
- 1.Al-Maktari M.T., Bassiouny H.K., Al-Hamd Z.S., Assabri A.M., El-Massry A.G., Shatat H.Z. Malaria status in Al-Hodeidah Governorate, Yemen: malariometric parasitic survey & chloroquine resistance P. falciparum local strain. Journal of the Egyptian Society of Parasitology. 2003;33:361–372. [PubMed] [Google Scholar]
- 2.Lekweiry K.M., Abdallahi M.O., Ba H., Arnathau C., Durand P., Trape J.F. Preliminary study of malaria incidence in Nouakchott, Mauritania. Malaria Journal. 2009;8:92–98. doi: 10.1186/1475-2875-8-92. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Win T.T., Lin K., Mizuno S., Zhou M., Liu Q., Ferreira M.U. Wide distribution of Plasmodium ovale in Myanmar. Tropical Medicine & International Health. 2002;7:231–239. doi: 10.1046/j.1365-3156.2002.00857.x. [DOI] [PubMed] [Google Scholar]
- 4.Galinski M.R., Barnwell J.W. Monkey malaria kills four humans. Trends in Parasitology. 2009;25:200–204. doi: 10.1016/j.pt.2009.02.002. [DOI] [PubMed] [Google Scholar]
- 5.Mueller I., Zimmerman P.A., Reeder J.C. Plasmodium malariae and Plasmodium ovale — the “bashful” malaria parasites. Trends in Parasitology. 2007;23:278–283. doi: 10.1016/j.pt.2007.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Kawamoto F., Liu Q., Ferreira M.U., Tantular I.S. How prevalent are Plasmodium ovale and P. malariae in East Asia? Parasitology Today. 1999;15:422–426. doi: 10.1016/s0169-4758(99)01511-2. [DOI] [PubMed] [Google Scholar]
- 7.Bass C., Nikou D., Blagborough A.M., Vontas J., Sinden R.E., Williamson M.S. PCR-based detection of Plasmodium in Anopheles mosquitoes: a comparison of a new high-throughput assay with existing methods. Malaria Journal. 2008;7:177–185. doi: 10.1186/1475-2875-7-177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Imwong M., Pukrittayakamee S., Renia L., Letourneur F., Charlieu J.P., Leartsakulpanich U. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrobial Agents and Chemotherapy. 2003;47:1514–1521. doi: 10.1128/AAC.47.5.1514-1521.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hastings M.D., Sibley C.H. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:13137–13141. doi: 10.1073/pnas.182295999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Tahar R., de Pecoulas P.E., Basco L.K., Chiadmi M., Mazabraud A. Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli. Molecular and Biochemical Parasitology. 2001;113:241–249. doi: 10.1016/s0166-6851(01)00230-4. [DOI] [PubMed] [Google Scholar]
- 11.Le Bras J., Deloron P., Ricour A., Andrieu B., Savel J., Coulaud J.P. Plasmodium falciparum: drug sensitivity in vitro of isolates before and after adaptation to continuous culture. Experimental Parasitology. 1983;56:9–14. doi: 10.1016/0014-4894(83)90091-7. [DOI] [PubMed] [Google Scholar]
- 12.Sutherland C.J., Tanomsing N., Nolder D., Oguike M., Jennison C., Pukrittayakamee S. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. Journal of Infectious Diseases. 2010;201:1544–1550. doi: 10.1086/652240. [DOI] [PubMed] [Google Scholar]
- 13.Snounou G., Singh B. Nested PCR analysis of Plasmodium parasites. Methods in Molecular Medicine. 2002;72:189–203. doi: 10.1385/1-59259-271-6:189. [DOI] [PubMed] [Google Scholar]
- 14.Tanomsing N., Imwong M., Theppabutr S., Pukrittayakamee S., Day N.P., White N.J. Accurate and sensitive detection of Plasmodium species in humans by use of the dihydrofolate reductase-thymidylate synthase linker region. Journal of Clinical Microbiology. 2010;48:3735–3737. doi: 10.1128/JCM.00898-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Higuchi R., Krummel B., Saiki R.K. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Research. 1988;16:7351–7367. doi: 10.1093/nar/16.15.7351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Chanama M., Chitnumsub P., Yuthavong Y. Subunit complementation of thymidylate synthase in Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase. Molecular and Biochemical Parasitology. 2005;139:83–90. doi: 10.1016/j.molbiopara.2004.09.010. [DOI] [PubMed] [Google Scholar]
- 17.Meek T.D., Garvey E.P., Santi D.V. Purification and characterization of the bifunctional thymidylate synthetase-dihydrofolate reductase from methotrexate-resistant Leishmania tropica. Biochemistry. 1985;24:678–686. doi: 10.1021/bi00324a021. [DOI] [PubMed] [Google Scholar]
- 18.Hillcoat B.L., Nixon P.F., Blakley R.L. Effect of substrate decomposition on the spectrophotometric assay of dihydrofolate reductase. Analytical Biochemistry. 1967;21:178–189. doi: 10.1016/0003-2697(67)90179-0. [DOI] [PubMed] [Google Scholar]
- 19.Wahba A.J., Friedkin M. Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate. Journal of Biological Chemistry. 1961;236:PC11–PC12. [PubMed] [Google Scholar]
- 20.Roberts D. An isotopic assay for thymidylate synthetase. Biochemistry. 1966;5:3546–3548. doi: 10.1021/bi00875a022. [DOI] [PubMed] [Google Scholar]
- 21.Sirawaraporn W., Sirawaraporn R., Cowman A.F., Yuthavong Y., Santi D.V. Heterologous expression of active thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Biochemistry. 1990;29:10779–10785. doi: 10.1021/bi00500a009. [DOI] [PubMed] [Google Scholar]
- 22.Chitnumsub P., Yuvaniyama J., Vanichtanankul J., Kamchonwongpaisan S., Walkinshaw M.D., Yuthavong Y. Characterization, crystallization and preliminary X-ray analysis of bifunctional dihydrofolate reductase-thymidylate synthase from Plasmodium falciparum. Acta Crystallographica. Section D, Biological Crystallography. 2004;60:780–783. doi: 10.1107/S0907444904001544. [DOI] [PubMed] [Google Scholar]
- 23.Sirawaraporn W., Sathitkul T., Sirawaraporn R., Yuthavong Y., Santi D.V. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:1124–1129. doi: 10.1073/pnas.94.4.1124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Leartsakulpanich U., Imwong M., Pukrittayakamee S., White N.J., Snounou G., Sirawaraporn W. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Molecular and Biochemical Parasitology. 2002;119:63–73. doi: 10.1016/s0166-6851(01)00402-9. [DOI] [PubMed] [Google Scholar]
- 25.Tindall K.R., Kunkel T.A. Fidelity of DNA synthesis by the Thermus aquaticus DNA polymerase. Biochemistry. 1988;27:6008–6013. doi: 10.1021/bi00416a027. [DOI] [PubMed] [Google Scholar]
- 26.Bunyarataphan S., Leartsakulpanich U., Taweechai S., Tarnchompoo B., Kamchonwongpaisan S., Yuthavong Y. Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays. Antimicrobial Agents and Chemotherapy. 2006;50:3631–3637. doi: 10.1128/AAC.00448-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Taylor Ringia E.A., Garrett J.B., Thoden J.B., Holden H.M., Rayment I., Gerlt J.A. Evolution of enzymatic activity in the enolase superfamily: functional studies of the promiscuous o-succinylbenzoate synthase from Amycolatopsis. Biochemistry. 2004;43:224–229. doi: 10.1021/bi035815+. [DOI] [PubMed] [Google Scholar]
- 28.Sirawaraporn W., Prapunwattana P., Sirawaraporn R., Yuthavong Y., Santi D.V. The dihydrofolate reductase domain of Plasmodium falciparum thymidylate synthase-dihydrofolate reductase. Gene synthesis, expression, and anti-folate-resistant mutants. Journal of Biological Chemistry. 1993;268:21637–21644. [PubMed] [Google Scholar]
- 29.Beard W.A., Appleman J.R., Delcamp T.J., Freisheim J.H., Blakley R.L. Hydride transfer by dihydrofolate reductase. Causes and consequences of the wide range of rates exhibited by bacterial and vertebrate enzymes. Journal of Biological Chemistry. 1989;264:9391–9399. [PubMed] [Google Scholar]
- 30.Yuvaniyama J., Chitnumsub P., Kamchonwongpaisan S., Vanichtanankul J., Sirawaraporn W., Taylor P. Insights into antifolate resistance from malarial DHFR-TS structures. Nature Structural Biology. 2003;10:357–365. doi: 10.1038/nsb921. [DOI] [PubMed] [Google Scholar]
- 31.Chanama M., Chanama S., Shaw P.J., Chitnumsub P., Leartsakulpanich U., Yuthavong Y. Formation of catalytically active cross-species heterodimers of thymidylate synthase from Plasmodium falciparum and Plasmodium vivax. Molecular Biology Reports. 2011;38:1029–1037. doi: 10.1007/s11033-010-0199-7. [DOI] [PubMed] [Google Scholar]